comparemela.com

Latest Breaking News On - Ginko bioworks - Page 6 : comparemela.com

3 Life Science Stocks Cathy Wood s Buying Hand Over Fist Right Now

Maine creates pool COVID-19 testing program to help schools more fully reopen

Maine creates pool COVID-19 testing program to help schools more fully reopen © WMTW school covid-19 pool testing Pooled COVID-19 testing is the state’s newest tool to increase full-time in-person learning for more Maine children. The testing will be available to school districts statewide by mid-May.Sign up for our Newsletters Students are tested in classes, cohorts or in groups. The state has partnered with Ginkgo Bioworks for the pool testing program. Chief Commercial Officer Matthew McKnight said testing takes about 8 minutes per classroom. “They all swab their nose, 4 seconds on each side, and then they all drop their swabs and that classroom gets tested together as a group,” McKnight said.

Rep Auchincloss visits COVID-19 test site at Medfield High School

COURTESY OF THE OFFICE OF CONGRESSMAN JAKE AUCHINCLOSS Congressman Jake Auchincloss (D-4th District) and Ginkgo Bioworks staff recently toured the Medfield High School COVID-19 testing operation. Auchincloss visited the school as part of his American Rescue Plan tour, highlighting the success of the American Rescue Plan and the economic recovery taking place. Each stop in the district has focused on at least one of the three main goals of the ARP: shots in arms, kids back to school, and Americans back to work. “Medfield is a model for Massachusetts and for the nation,” said Auchincloss. “By following the best and latest public health guidance, by leveraging the best in science - in partnership with companies like Ginko Bioworks, - and by building close-knit collaboration built on confidence and transparency between students, parents, nurses, faculty and administrators, they have been able to achieve testing rates that have allowed them to get back to full time in-person learn

Why grandparents can t find vaccines: Scarcity of niche biotech ingredients

Why grandparents can’t find vaccines: Scarcity of niche biotech ingredients Christopher Rowland © James MacDonald/Bloomberg A scientist works in the Acuitas Therapeutics lab at the University of British Columbia in Vancouver, B.C., on Jan. 21, 2021. Acuitas Therapeutics provided its lipid nanoparticle delivery system in the development of the Pfizer-BioNTech coronavirus vaccine. (Photography by James MacDonald/Bloomberg News) Acuitas Therapeutics, a tiny biotechnology firm in Vancouver, B.C., has just 30 employees and leases its labs from the University of British Columbia. The company doesn’t even have a sign on its building. Until last year, it outsourced production of only small volumes of lipid nanoparticles, fat droplets used to deliver RNA into cells, for research and a single approved treatment for a rare disease.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.